Literature DB >> 23578725

Small molecule inhibitors of ER α-glucosidases are active against multiple hemorrhagic fever viruses.

Jinhong Chang1, Travis K Warren, Xuesen Zhao, Tina Gill, Fang Guo, Lijuan Wang, Mary Ann Comunale, Yanming Du, Dominic S Alonzi, Wenquan Yu, Hong Ye, Fei Liu, Ju-Tao Guo, Anand Mehta, Andrea Cuconati, Terry D Butters, Sina Bavari, Xiaodong Xu, Timothy M Block.   

Abstract

Host cellular endoplasmic reticulum α-glucosidases I and II are essential for the maturation of viral glycosylated envelope proteins that use the calnexin mediated folding pathway. Inhibition of these glycan processing enzymes leads to the misfolding and degradation of these viral glycoproteins and subsequent reduction in virion secretion. We previously reported that, CM-10-18, an imino sugar α-glucosidase inhibitor, efficiently protected the lethality of dengue virus infection of mice. In the current study, through an extensive structure-activity relationship study, we have identified three CM-10-18 derivatives that demonstrated superior in vitro antiviral activity against representative viruses from four viral families causing hemorrhagic fever. Moreover, the three novel imino sugars significantly reduced the mortality of two of the most pathogenic hemorrhagic fever viruses, Marburg virus and Ebola virus, in mice. Our study thus proves the concept that imino sugars are promising drug candidates for the management of viral hemorrhagic fever caused by variety of viruses.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23578725      PMCID: PMC3663898          DOI: 10.1016/j.antiviral.2013.03.023

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  44 in total

Review 1.  Exotic emerging viral diseases: progress and challenges.

Authors:  Thomas W Geisbert; Peter B Jahrling
Journal:  Nat Med       Date:  2004-12       Impact factor: 53.440

Review 2.  Pathogenesis of viral hemorrhagic fever.

Authors:  Mike Bray
Journal:  Curr Opin Immunol       Date:  2005-08       Impact factor: 7.486

Review 3.  Molecular virology of hepatitis B virus for clinicians.

Authors:  Timothy M Block; Haitao Guo; Ju-Tao Guo
Journal:  Clin Liver Dis       Date:  2007-11       Impact factor: 6.126

4.  A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs.

Authors:  Wouter Schul; Wei Liu; Hao-Ying Xu; Marie Flamand; Subhash G Vasudevan
Journal:  J Infect Dis       Date:  2007-01-23       Impact factor: 5.226

5.  Antiviral profiles of novel iminocyclitol compounds against bovine viral diarrhea virus, West Nile virus, dengue virus and hepatitis B virus.

Authors:  Baohua Gu; Peter Mason; Lijuan Wang; Pamela Norton; Nigel Bourne; Robert Moriarty; Anand Mehta; Mehendra Despande; Rajendra Shah; Timothy Block
Journal:  Antivir Chem Chemother       Date:  2007

6.  Antiviral drug therapy of filovirus infections: S-adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model.

Authors:  J Huggins; Z X Zhang; M Bray
Journal:  J Infect Dis       Date:  1999-02       Impact factor: 5.226

7.  Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus.

Authors:  Eike Steinmann; Thomas Whitfield; Stephanie Kallis; Raymond A Dwek; Nicole Zitzmann; Thomas Pietschmann; Ralf Bartenschlager
Journal:  Hepatology       Date:  2007-08       Impact factor: 17.425

Review 8.  Roles of N-linked glycans in the endoplasmic reticulum.

Authors:  Ari Helenius; Markus Aebi
Journal:  Annu Rev Biochem       Date:  2004       Impact factor: 23.643

9.  Cellular effects of deoxynojirimycin analogues: inhibition of N-linked oligosaccharide processing and generation of free glucosylated oligosaccharides.

Authors:  Howard R Mellor; David C A Neville; David J Harvey; Frances M Platt; Raymond A Dwek; Terry D Butters
Journal:  Biochem J       Date:  2004-08-01       Impact factor: 3.857

10.  Glucosylated free oligosaccharides are biomarkers of endoplasmic- reticulum alpha-glucosidase inhibition.

Authors:  Dominic S Alonzi; David C A Neville; Robin H Lachmann; Raymond A Dwek; Terry D Butters
Journal:  Biochem J       Date:  2008-01-15       Impact factor: 3.857

View more
  40 in total

1.  Ester Prodrugs of IHVR-19029 with Enhanced Oral Exposure and Prevention of Gastrointestinal Glucosidase Interaction.

Authors:  Julia Ma; Shuo Wu; Xuexiang Zhang; Fang Guo; Katherine Yang; Jia Guo; Qing Su; Huagang Lu; Patrick Lam; Yuhuan Li; Zhengyin Yan; William Kinney; Ju-Tao Guo; Timothy M Block; Jinhong Chang; Yanming Du
Journal:  ACS Med Chem Lett       Date:  2017-01-17       Impact factor: 4.345

2.  Structures of mammalian ER α-glucosidase II capture the binding modes of broad-spectrum iminosugar antivirals.

Authors:  Alessandro T Caputo; Dominic S Alonzi; Lucia Marti; Ida-Barbara Reca; J L Kiappes; Weston B Struwe; Alice Cross; Souradeep Basu; Edward D Lowe; Benoit Darlot; Angelo Santino; Pietro Roversi; Nicole Zitzmann
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-26       Impact factor: 11.205

3.  Inhibition of endoplasmic reticulum-resident glucosidases impairs severe acute respiratory syndrome coronavirus and human coronavirus NL63 spike protein-mediated entry by altering the glycan processing of angiotensin I-converting enzyme 2.

Authors:  Xuesen Zhao; Fang Guo; Mary Ann Comunale; Anand Mehta; Mohit Sehgal; Pooja Jain; Andrea Cuconati; Hanxin Lin; Timothy M Block; Jinhong Chang; Ju-Tao Guo
Journal:  Antimicrob Agents Chemother       Date:  2014-10-27       Impact factor: 5.191

Review 4.  Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond.

Authors:  Veaceslav Boldescu; Mira A M Behnam; Nikos Vasilakis; Christian D Klein
Journal:  Nat Rev Drug Discov       Date:  2017-05-05       Impact factor: 84.694

5.  Enhancing the antiviral potency of ER α-glucosidase inhibitor IHVR-19029 against hemorrhagic fever viruses in vitro and in vivo.

Authors:  Julia Ma; Xuexiang Zhang; Veronica Soloveva; Travis Warren; Fang Guo; Shuo Wu; Huagang Lu; Jia Guo; Qing Su; Helen Shen; Eric Solon; Mary Ann Comunale; Anand Mehta; Ju-Tao Guo; Sina Bavari; Yanming Du; Timothy M Block; Jinhong Chang
Journal:  Antiviral Res       Date:  2017-12-15       Impact factor: 5.970

6.  Identification of Residues Controlling Restriction versus Enhancing Activities of IFITM Proteins on Entry of Human Coronaviruses.

Authors:  Xuesen Zhao; Mohit Sehgal; Zhifei Hou; Junjun Cheng; Sainan Shu; Shuo Wu; Fang Guo; Sylvain J Le Marchand; Hanxin Lin; Jinhong Chang; Ju-Tao Guo
Journal:  J Virol       Date:  2018-02-26       Impact factor: 5.103

7.  Could the Ebola virus matrix protein VP40 be a drug target?

Authors:  Robert V Stahelin
Journal:  Expert Opin Ther Targets       Date:  2013-11-28       Impact factor: 6.902

8.  Pathophysiology of Ebola Virus Infection: Current Challenges and Future Hopes.

Authors:  Andrea Rivera; Ilhem Messaoudi
Journal:  ACS Infect Dis       Date:  2015-03-30       Impact factor: 5.084

9.  A Novel Benzodiazepine Compound Inhibits Yellow Fever Virus Infection by Specifically Targeting NS4B Protein.

Authors:  Fang Guo; Shuo Wu; Justin Julander; Julia Ma; Xuexiang Zhang; John Kulp; Andrea Cuconati; Timothy M Block; Yanming Du; Ju-Tao Guo; Jinhong Chang
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

10.  Therapeutics for postexposure treatment of Ebola virus infection.

Authors:  Marina Jerebtsova; Sergei Nekhai
Journal:  Future Virol       Date:  2015-03       Impact factor: 1.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.